Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial

Francesco Travaglino, Veronica Russo, Benedetta De Berardinis, Filippo Numeroso, Pamela Catania, Gianfranco Cervellin, Stefano Geniere Nigra, Francesco Geraci, Maria Antonietta Bressan, Stefania Guerrini, Mario Cavazza, Christian Folli, Valter Monzani, Stefania Battista, Giulio Mengozzi, Paola Noto, Giuseppe Carpinteri, Andrea Semplicini, Federica Stella, Stella IngrassiaPaolo Moscatelli, Patrizia Giuntini, Gerardo Salerno, Patrizia Cardelli, Salvatore Di Somma

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea. Methods To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF). Results Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P

Original languageEnglish
Pages (from-to)334-341
Number of pages8
JournalAmerican Journal of Emergency Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Emergency Medicine

Fingerprint Dive into the research topics of 'Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial'. Together they form a unique fingerprint.

Cite this